"Nevirapine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
| Descriptor ID |
D019829
|
| MeSH Number(s) |
D03.383.725.506
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nevirapine".
Below are MeSH descriptors whose meaning is more specific than "Nevirapine".
This graph shows the total number of publications written about "Nevirapine" by people in this website by year, and whether "Nevirapine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nevirapine" by people in Profiles.
-
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients. PLoS One. 2015; 10(6):e0129100.
-
Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS. 2010 Jan 02; 24(1):109-14.
-
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS. 2009 Nov 27; 23(18):2425-30.
-
Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004 Feb 01; 35(2):120-5.
-
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002 Mar 01; 185(5):599-607.
-
Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA. 2000 Dec 06; 284(21):2723.
-
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997 Jun 15; 126(12):929-38.